Furthermore, high levels of CRELD2 in breast cancers were associated with reduced overall survival, invasiveness and triple‐negative status (in which the loss of the estrogen receptor, progesterone receptor and the human epidermal growth factor receptor 2 results in a highly aggressive form of cancer), in human breast cancer patients (Boyle et al., 2020). Here, ERBB2 is linked to breast carcinoma.